Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

1. Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening at 11-13 Weeks Gestation

Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening at 11-13 Weeks Gestation "Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening " by Lauren Voelker and Mergitu Gemeda < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background:Approximately 3% of pregnant women develop preeclampsia at some time during their pregnancy. Preeclampsia (...) is a common cause of maternal and fetal morbidity and mortality worldwide. Currently there are 3 assessment tools for preeclampsia: the National Institute for Health and Care Excellence (NICE) guidelines, the American College of Obstetricians and Gynecologist (ACOG) and the Fetal Medicine Foundation (FMF) algorithm. Both NICE and ACOG guidelines use maternal demographics and medical history as a screening tool. The more recent approach, FMF uses Bayes theorem utilizes biophysical and biochemical markers

2019 Pacific University EBM Capstone Project

2. Predictive performance of the competing risk model in screening for preeclampsia

Predictive performance of the competing risk model in screening for preeclampsia The established method of screening for preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors the patient is classified as high risk and in their absence as low risk. However, the performance of such an approach is poor. We developed a competing risks model, which allows combination of maternal factors (age, weight, height, race (...) , parity, personal and family history of preeclampsia, chronic hypertension, diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, method of conception and interpregnancy interval), with biomarkers to estimate the individual patient-specific risks of preeclampsia requiring delivery before any specified gestation. The performance of this approach is by far superior to that of the risk scoring systems.The objective of the study was to examine the predictive performance

2019 EvidenceUpdates

3. Gestational Hypertension and Preeclampsia

Gestational Hypertension and Preeclampsia Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

4. The relationship between NSAID use and worsening hypertension among postpartum women with preeclampsia

The relationship between NSAID use and worsening hypertension among postpartum women with preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

5. Aspirin in the prevention of preeclampsia in women with pre-existing diabetes: systematic review (and meta-analysis)

Aspirin in the prevention of preeclampsia in women with pre-existing diabetes: systematic review (and meta-analysis) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

6. The best magnesium sulfate regimen in preeclampsia prevention

The best magnesium sulfate regimen in preeclampsia prevention Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

7. The prevention of preeclampsia with prophylactic aspirin: a systematic review

The prevention of preeclampsia with prophylactic aspirin: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

8. The association between a history of hypertensive disorders of pregnancy (HDP) (preeclampsia or gestational hypertension) and the elevated risk of postpregnancy type 2 diabetes

The association between a history of hypertensive disorders of pregnancy (HDP) (preeclampsia or gestational hypertension) and the elevated risk of postpregnancy type 2 diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

9. A systematic review of the impact of social and economic determinants of health and the occurrence of preeclampsia

A systematic review of the impact of social and economic determinants of health and the occurrence of preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

10. Deficiency of vitamin D during pregnancy. Preeclampsia and prematurity

Deficiency of vitamin D during pregnancy. Preeclampsia and prematurity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

11. The association of gestational thyroid function and thyroid autoimmunity with gestational hypertension and preeclampsia

The association of gestational thyroid function and thyroid autoimmunity with gestational hypertension and preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

12. Studies reporting on the diagnostic accuracy of ophthalmic artery Doppler for preeclampsia

Studies reporting on the diagnostic accuracy of ophthalmic artery Doppler for preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

13. Prevalence, incidence, trends and associated factors of preeclampsia among pregnant women in sub Saharan Africa: a systematic review and meta-analysis

Prevalence, incidence, trends and associated factors of preeclampsia among pregnant women in sub Saharan Africa: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

14. Hepatic rupture in preeclampsia and HELLP Syndrome: review of a catastrophic presentation

Hepatic rupture in preeclampsia and HELLP Syndrome: review of a catastrophic presentation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

15. Is aspirin effective in reducing the rate of preeclampsia when it is initiated before 11 weeks of gestation as compared to placebo?

Is aspirin effective in reducing the rate of preeclampsia when it is initiated before 11 weeks of gestation as compared to placebo? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

16. Maternal risk for cardiovascular disease after pregnancies complicated by preeclampsia: a systematic review and meta-analysis

Maternal risk for cardiovascular disease after pregnancies complicated by preeclampsia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

17. Markers of podocyte dysfunction in preeclampsia: a systematic review and meta-analysis

Markers of podocyte dysfunction in preeclampsia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

18. Doppler parameters of renal hemodynamics in women with preeclampsia: a systematic review and network meta-analysis

Doppler parameters of renal hemodynamics in women with preeclampsia: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

19. Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial

Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia.We conducted a randomized, double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery (...) , women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5 or by the time of hospital discharge. Assuming a 50% rate of persistent hypertension in women with preeclampsia, 118 participants were required to detect a 50% rate reduction. Analyses were by intention to treat.From August 2016 to September

2018 EvidenceUpdates

20. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial

Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial Preterm preeclampsia has a high rate of fetal death or disability. There is no treatment to slow the disease, except delivery. Preclinical studies have identified proton pump inhibitors as a possible treatment.The purpose of this study was to examine whether esomeprazole could prolong pregnancy in women who have received a diagnosis of preterm preeclampsia.We performed a double-blind, randomized (...) controlled trial at Tygerberg Hospital in South Africa. Women with preterm preeclampsia (gestational age 26 weeks+0 days to 31 weeks+6 days) were assigned randomly to 40-mg daily esomeprazole or placebo. The primary outcome was a prolongation of gestation of 5 days. Secondary outcomes were maternal and neonatal outcomes. We compared circulating markers of endothelial dysfunction that was associated with preeclampsia and performed pharmacokinetic studies.Between January 2016 and April 2017, we recruited

2018 EvidenceUpdates